Korro Bio Announces 34% Workforce Reduction To Extend Cash Runway Into Second Half Of 2027 To Provide Sufficient Capital To Deliver Clinical Data From KRRO-121; Estimates That It Will Incur One-time Restructuring Charges Of ~$2.4M

Approximately 34% reduction in workforce impacting all levels of the organization.

• Extending cash runway into second half of 2027 to provide sufficient capital to deliver clinical data from KRRO-121, advance at least one additional program, and execute partnership discussions to broaden pipeline development.
• Korro estimates that it will incur one-time restructuring charges of approximately $2.4 million including employee severance, benefits, and related termination costs, the majority of which Korro expects to recognize during the fourth quarter of 2025.